Alta Fundamental Advisers’s Indivior Pharmaceuticals INDV Stock Holding History

Alta Fundamental Advisers’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$16.6M	Sell	404,529 -5,000	-1%	-$181K	4.98%	5
2026 Q1	$12.5M	Hold	409,529	–	–	4.7%	7
2025 Q4	$14.7M	Sell	409,529 -65,520	-14%	-$2M	6.62%	5
2025 Q3	$11.5M	Sell	475,049 -100,000	-17%	-$2.09M	4.89%	8
2025 Q2	$8.48M	Buy	575,049 +240,580	+72%	+$2.8M	4.34%	8
2025 Q1	$3.19M	Sell	334,469 -65,531	-16%	-$689K	2.05%	16
2024 Q4	$4.97M	Buy	400,000 +75,000	+23%	+$772K	1.49%	17
2024 Q3	$2.39M	Hold	325,000	–	–	0.69%	21
2024 Q2	$4.03M	Buy	325,000 +175,000	+117%	+$3.16M	1.28%	14
2024 Q1	$2.54M	Hold	150,000	–	–	0.96%	16
2023 Q4	$1.78M	Hold	150,000	–	–	0.8%	16
2023 Q3	$2.67M	Hold	150,000	–	–	1.27%	11
2023 Q2	$2.73M	Buy	+150,000	New	+$3.44M	1.33%	9

Other funds holding INDV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

OCM

Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Alta Fundamental Advisers's INDV Position: Q2 2026 in Review

Alta Fundamental Advisers reduced its Indivior Pharmaceuticals (INDV) stake by 1.2% in Q2 2026, selling an estimated $181K and leaving 404,529 shares worth $16.6M. The position accounts for 4.98% of the portfolio, ranked #5.

Alta Fundamental Advisers first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

Alta Fundamental Advisers held 404,529 shares of Indivior Pharmaceuticals worth $16.6M as of Q2 2026.
Alta Fundamental Advisers sold 5,000 Indivior Pharmaceuticals shares in Q2 2026, an estimated $181K.
Indivior Pharmaceuticals made up 4.98% of Alta Fundamental Advisers's portfolio in Q2 2026, its #5 holding.
Alta Fundamental Advisers first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Alta Fundamental Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.